Monogram Technologies (MGRM) investor relations material

Executive summary

• Entered into a definitive merger agreement with Zimmer Biomet; all shares to be converted to cash and contingent value rights upon closing, subject to customary conditions.

• Achieved FDA 510(k) clearance for the mBôs™ TKA System, enabling initial commercialization efforts.

• Terminated Mount Sinai license agreement, incurring a $4.0 million settlement, including $500,000 cash and $3.5 million in Series E Preferred Stock.

• Completed first fully autonomous saw-based robotic knee replacement in a live patient, initiating a 102-patient clinical trial in India.

Financial highlights

• Net loss of $5.4 million for Q2 2025, a 54% increase year-over-year; net loss of $8.6 million for the six months ended June 30, 2025, up 23% year-over-year.

• Operating expenses decreased 15% in Q2 2025 year-over-year, driven by lower R&D, marketing, and G&A costs.

• Cash and cash equivalents were $12.8 million as of June 30, 2025; working capital of $7.2 million and total stockholders' equity of $8.6 million.

• No product revenue recognized in the quarter; FDA clearance allows for future sales.

• $2.5 million one-time charge related to Mount Sinai settlement impacted quarterly results.

Outlook and guidance

• Existing cash resources expected to fund operations through the anticipated merger closing.

• If the merger is not completed, a $15 million loan facility from Zimmer Biomet is available to support at least six months of operations.

• Commercialization of the mBôs™ TKA System to proceed, with initial placements targeting key surgeons and strategic geographies.